Eisai Declines Most in Four Months on Aricept Sales Prospects

Eisai Co., the maker of Aricept, the world’s best-selling treatment for Alzheimer’s disease, fell the most in four months in Tokyo trading on concern that efforts to maintain demand for the drug may not work.

Eisai slumped 2.8 percent to 3,105 yen on the Tokyo Stock Exchange at 12:47 p.m., the most since March 29. Aricept sales plunged 49 percent to 42 billion yen in the three months ended June 30, the Tokyo-based company said yesterday.

A company strategy to prevent patients being prescribed alternatives to Aricept and another best-selling Eisai medicine in the U.S. “appears likely to end in failure,” Credit Suisse AG analysts said in a report today.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.